Biography

Amir H. Shojaei was named Harrow’s Chief Scientific Officer in January 2025, bringing with him nearly 30 years of experience in the life sciences sector. A recognized leader in clinical development, regulatory affairs, and the commercialization of biopharmaceutical and biologic products, Dr. Shojaei oversees Harrow’s medical and clinical affairs, regulatory affairs, pharmacovigilance and QA/compliance for FDA-approved products. Throughout his career, Dr. Shojaei has been instrumental in the advancement of innovative treatments for anterior and posterior segment eye diseases. Notable, he led the development and FDA approval of Xiidra®, a groundbreaking therapy and the first product to treat both the signs and symptoms of dry eye disease. Prior to joining Harrow, he held senior leadership roles at several prominent biopharmaceutical companies, including AsclepiX Therapeutics, TherOptix, Novartis Pharmaceuticals, and Shire Pharmaceuticals (acquired by Takeda). Dr. Shojaei holds a Pharm.D. and Ph.D. from the University of the Pacific. In addition, he is the holder of multiple patents and has authored over 25 peer-reviewed publications.